Edwards Lifesciences Corporation $EW Shares Sold by Highview Capital Management LLC DE

Highview Capital Management LLC DE lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 65.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,775 shares of the medical research company’s stock after selling 5,250 shares during the quarter. Highview Capital Management LLC DE’s holdings in Edwards Lifesciences were worth $217,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences in the first quarter worth $26,000. SouthState Corp acquired a new position in Edwards Lifesciences during the 1st quarter worth $27,000. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences during the 2nd quarter worth about $28,000. Costello Asset Management INC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $29,000. Finally, NewSquare Capital LLC boosted its stake in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.7%

Shares of NYSE EW opened at $84.13 on Wednesday. The business has a 50-day moving average price of $78.37 and a 200 day moving average price of $77.88. The stock has a market cap of $48.82 billion, a PE ratio of 12.11, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.21.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the topic of several analyst reports. Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. Canaccord Genuity Group reiterated a “hold” rating and set a $84.00 target price (up previously from $81.00) on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Stifel Nicolaus raised their price target on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Evercore ISI lifted their price target on Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.39.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.